William A Weiss

List of Publications by Year
in descending order

143	21,286	16451 64	9861 141
papers	citations	h-index	g-index

146	146	146	32626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nature Medicine, 2022, 28, 333-344.	30.7	105
2	Nuclear tetraspanin 8 promotes breast cancer progression. Cell Research, 2022, 32, 511-512.	12.0	1
3	A SHHecret target of relapsed medulloblastoma: Astrocytes. Journal of Experimental Medicine, 2021, 218, .	8.5	0
4	Drugging the â€œUndruggableâ€•MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Research, 2021, 81, 1627-1632.	0.9	25
5	All eyes on a phosphatase in glioma stem cells. Journal of Experimental Medicine, 2021, 218, .	8.5	0
6	Betacellulin drives therapy resistance in glioblastoma. Neuro-Oncology, 2020, 22, 457-469.	1.2	8
7	Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype. Neuro-Oncology, 2020, 22, 175-176.	1.2	2
8	Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation. Molecular Cancer Therapeutics, 2020, 19, 1328-1339.	4.1	17
9	Utility of Human-Derived Models for Glioblastoma. Cancer Discovery, 2020, 10, 907-909.	9.4	6
10	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. Clinical Cancer Research, 2020, 26, 2457-2460.	7.0	8
11	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Molecular Cancer Therapeutics, 2019, 18, 1565-1576.	4.1	11
12	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. Cell Stem Cell, 2019, 25, 433-446.e7.	11.1	56
13	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. Blood, 2019, 133, 1119-1129.	1.4	99
14	A CK1Î± Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. Clinical Cancer Research, 2019, 25, 1379-1388.	7.0	20
15	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene, 2018, 37, 2850-2862.	5.9	71
16	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1â€“TGF-Î²â€“OTX2â€“SNAIL via PTEN inhibition. Brain, 2018, 141, 1300-1319.	7.6	22
17	Antisecretory Factorâ€“Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. Molecular Cancer Research, 2018, 16, 777-790.	3.4	16
18	Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene, 2018, 37, 1561-1575.	5.9	383

#	Article	IF	Citations
19	Inhibiting 4EBP1 in Glioblastoma. Clinical Cancer Research, 2018, 24, 14-21.	7.0	34
20	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	1.2	116
21	EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Research, 2018, 78, 6785-6794.	0.9	44
22	Dual HDAC and PI3K Inhibition Abrogates NFÎºB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Research, 2018, 78, 4007-4021.	0.9	60
23	An oncolytic measles virusâ€“sensitive Group 3 medulloblastoma model in immune-competent mice. Neuro-Oncology, 2018, 20, 1606-1615.	1.2	19
24	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	1.2	217
25	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell, 2017, 31, 424-435.	16.8	138
26	Cross-activating c-Met/Î²1 integrin complex drives metastasis and invasive resistance in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8685-E8694.	7.1	60
27	Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell, 2017, 32, 395-397.	16.8	4
28	Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. Oncogene, 2017, 36, 6306-6314.	5.9	19
29	Glioblastoma cellular cross-talk converges on NF-ÎºB to attenuate EGFR inhibitor sensitivity. Genes and Development, 2017, 31, 1212-1227.	5.9	53
30	Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Journal of Neuro-Oncology, 2017, 131, 495-505.	2.9	29
31	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. Journal of Clinical Investigation, 2017, 128, 446-462.	8.2	117
32	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. Oncotarget, 2017, 8, 583-595.	1.8	24
33	Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo. Protein Science, 2016, 25, 308-315.	7.6	27
34	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Clinical Cancer Research, 2016, 22, 5312-5321.	7.0	39
35	Cholesterol: An Achillesâ€™ Heel for Glioblastoma?. Cancer Cell, 2016, 30, 653-654.	16.8	14
36	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266

#	Article	IF	Citations
37	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology, 2016, 126, 385-393.	2.9	31
38	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
39	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget, 2016, 7, 57525-57544.	1.8	42
40	IKK/NF-ÎºB signaling contributes to glioblastoma stem cell maintenance. Oncotarget, 2016, 7, 69173-69187.	1.8	37
41	Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology, 2015, 5, 111.	2.8	20
42	Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma. Molecular Cancer Therapeutics, 2015, 14, 419-428.	4.1	23
43	A new â€œangleâ€•on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition. Molecular and Cellular Oncology, 2015, 2, e975641.	0.7	5
44	The Genetics of Splicing in Neuroblastoma. Cancer Discovery, 2015, 5, 380-395.	9.4	20
45	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	16.8	165
46	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clinical Cancer Research, 2015, 21, 3750-3758.	7.0	40
47	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nature Neuroscience, 2015, 18, 1236-1246.	14.8	74
48	STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. Cancer Research, 2015, 75, 4302-4311.	0.9	70
49	Alternative splicing in cancer: implications for biology and therapy. Oncogene, 2015, 34, 1-14.	5.9	247
50	EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget, 2015, 6, 21993-22005.	1.8	27
51	Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma. Cell Reports, 2014, 9, 1034-1046.	6.4	28
52	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 2014, 134, 2437-2447.	5.1	100
53	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506, 445-450.	27.8	521
54	The prenatal origins of cancer. Nature Reviews Cancer, 2014, 14, 277-289.	28.4	201

#	Article	IF	Citations
55	BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. Clinical Cancer Research, 2014, 20, 912-925.	7.0	296
56	Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. Science, 2014, 343, 189-193.	12.6	1,147
57	When Deletions Gain Functions: Commandeering Epigenetic Mechanisms. Cancer Cell, 2014, 26, 160-161.	16.8	6
58	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
59	Drugging MYCN through an Allosteric Transition in Aurora Kinase A. Cancer Cell, 2014, 26, 414-427.	16.8	231
60	Glial Progenitors as Targets for Transformation in Glioma. Advances in Cancer Research, 2014, 121, 1-65.	5.0	38
61	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 2013, 125, 373-384.	7.7	169
62	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1480-9.	7.1	37
63	EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma. Cancer Cell, 2013, 24, 438-449.	16.8	219
64	Starvation favors glioma stem cells. Nature Neuroscience, 2013, 16, 1359-1361.	14.8	4
65	Th-MYCN Mice with Caspase-8 Deficiency Develop Advanced Neuroblastoma with Bone Marrow Metastasis. Cancer Research, 2013, 73, 4086-4097.	0.9	57
66	What underlies the diversity of brain tumors?. Cancer and Metastasis Reviews, 2013, 32, 5-24.	5.9	16
67	Recapitulating human cancer in a mouse. Nature Biotechnology, 2013, 31, 392-395.	17.5	7
68	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
69	Blockade of Glioma Proliferation Through Allosteric Inhibition of JAK2. Science Signaling, 2013, 6, ra55.	3.6	23
70	G34, Another Connection between MYCN and a Pediatric Tumor. Cancer Discovery, 2013, 3, 484-486.	9.4	7
71	It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma. Clinical Cancer Research, 2013, 19, 5811-5813.	7.0	17
72	Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a014415-a014415.	6.2	480

#	Article	IF	Citations
73	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery, 2013, 3, 308-323.	9.4	549
74	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
75	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics, 2013, 8, 1254-1260.	2.7	16
76	Imaging-based chemical screening reveals activity-dependent neural differentiation of pluripotent stem cells. ELife, 2013, 2, e00508.	6.0	13
77	Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers. Cancer Discovery, 2012, 2, 450-457.	9.4	53
78	Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma. Science Translational Medicine, 2012, 4, 115ra3.	12.4	76
79	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-Oncology, 2012, 14, 1146-1152.	1.2	85
80	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes and Development, 2012, 26, 1780-1796.	5.9	68
81	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
82	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Child's Nervous System, 2012, 28, 521-532.	1.1	19
83	Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12722-12727.	7.1	34
84	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
85	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. Cancer Investigation, 2012, 30, 343-363.	1.3	9
86	Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature, 2012, 482, 529-533.	27.8	376
87	Cooperative interactions of BRAF ^{V600E} kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8710-8715.	7.1	77
88	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica, 2012, 123, 515-527.	7.7	66
89	Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathologica, 2012, 123, 485-499.	7.7	28
90	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. Cancer Cell, 2012, 21, 601-613.	16.8	177

#	Article	IF	Citations
91	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Letters, 2011, 306, 223-229.	7.2	66
92	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. Clinical Cancer Research, 2011, 17, 654-666.	7.0	789
93	Genetically engineered murine models â€“ Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Seminars in Cancer Biology, 2011, 21, 245-255.	9.6	48
94	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	16.8	494
95	Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma Precursors. Cancer Cell, 2011, 20, 328-340.	16.8	200
96	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Child's Nervous System, 2011, 27, 1243-1249.	1.1	21
97	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathologica, 2011, 122, 231-240.	7.7	195
98	Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems. Clinical Cancer Research, 2011, 17, 2339-2349.	7.0	61
99	Targeted Therapy for BRAFV600E Malignant Astrocytoma. Clinical Cancer Research, 2011, 17, 7595-7604.	7.0	143
100	Autophagy and Akt promote survival in glioma. Autophagy, 2011, 7, 536-538.	9.1	47
101	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncology, 2011, 13, 384-392.	1.2	139
102	Radiation dose estimation using preclinical imaging with â€metaiodobenzylguanidine (MIBG) PET. Medical Physics, 2010, 37, 4861-4867.	3.0	60
103	Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma. Science Signaling, 2010, 3, ra81.	3.6	253
104	Non-Stem Cell Origin for Oligodendroglioma. Cancer Cell, 2010, 18, 669-682.	16.8	211
105	Myc proteins as therapeutic targets. Oncogene, 2010, 29, 1249-1259.	5.9	177
106	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Medicine, 2010, 16, 1134-1140.	30.7	180
107	Intratumoral Therapy of Glioblastoma Multiforme Using Genetically Engineered Transferrin for Drug Delivery. Cancer Research, 2010, 70, 4520-4527.	0.9	36
108	Pleiotropic role forMYCNin medulloblastoma. Genes and Development, 2010, 24, 1059-1072.	5.9	146

#	Article	IF	Citations
109	A translational end-run for a rare, genetically enigmatic tumor. Cancer Biology and Therapy, 2009, 8, 2396-2397.	3.4	0
110	Whole-Body Sleeping Beauty Mutagenesis Can Cause Penetrant Leukemia/Lymphoma and Rare High-Grade Glioma without Associated Embryonic Lethality. Cancer Research, 2009, 69, 8429-8437.	0.9	72
111	Adenovirusâ€mediated hPNPase^{oldâ€35} gene transfer as a therapeutic strategy for neuroblastoma. Journal of Cellular Physiology, 2009, 219, 707-715.	4.1	13
112	Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene, 2009, 28, 3121-3131.	5.9	87
113	PI3K Signaling in Gliomaâ€"Animal Models and Therapeutic Challenges. Brain Pathology, 2009, 19, 112-120.	4.1	110
114	The Side Story of Stem-like Glioma Cells. Cell Stem Cell, 2009, 4, 191-192.	11.1	8
115	EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma. Science Signaling, 2009, 2, ra4.	3.6	153
116	Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity. EMBO Reports, 2008, 9, 923-929.	4.5	106
117	Chemotherapy-Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction. Neoplasia, 2008, 10, 1268-IN34.	5.3	57
118	Characterization of structurally distinct, isoform-selective phosphoinositide 3â€²-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Molecular Cancer Therapeutics, 2008, 7, 841-850.	4.1	66
119	BMPs oppose Math1 in cerebellar development and in medulloblastoma: Figure 1.. Genes and Development, 2008, 22, 693-699.	5.9	27
120	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. Cancer Research, 2007, 67, 9435-9442.	0.9	58
121	A Dual Phosphoinositide-3-Kinase Î±/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN-Mutant Glioma. Cancer Research, 2007, 67, 7960-7965.	0.9	199
122	Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. Journal of Cellular Biochemistry, 2007, 102, 1529-1541.	2.6	34
123	Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nature Chemical Biology, 2007, 3, 739-744.	8.0	260
124	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology, 2007, 3, 229-238.	8.0	190
125	A Pharmacological Map of the PI3-K Family Defines a Role for p110Î± in Insulin Signaling. Cell, 2006, 125, 733-747.	28.9	1,074
126	Chemical genetic approaches to the development of cancer therapeutics. Current Opinion in Genetics and Development, 2006, 16, 85-91.	3.3	3

#	Article	IF	Citations
127	Brain Tumors in S100Î²-v-erbB Transgenic Rats. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1111-1117.	1.7	13
128	Childhood tumors of the nervous system as disorders of normal development. Current Opinion in Pediatrics, 2006, 18, 634-638.	2.0	92
129	A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006, 9, 341-349.	16.8	575
130	Isoform Specific Inhibitors of PI3 Kinase in Glioma. Cell Cycle, 2006, 5, 2301-2305.	2.6	33
131	Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer Research, 2006, 66, 8139-8146.	0.9	186
132	Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nature Genetics, 2005, 37, 645-651.	21.4	148
133	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene, 2005, 24, 829-837.	5.9	41
134	Shared Epigenetic Mechanisms in Human and Mouse Gliomas Inactivate Expression of the Growth Suppressor SLC5A8. Cancer Research, 2005, 65, 3617-3623.	0.9	63
135	Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12664-12669.	7.1	137
136	Can mouse models for brain tumors inform treatment in pediatric patients?. Seminars in Cancer Biology, 2004, 14, 71-77.	9.6	1
137	Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. Journal of the National Cancer Institute, 2003, 95, 1394-1403.	6.3	96
138	Neural Stem Cell Biology May Be Well Suited for Improving Brain Tumor Therapies. Cancer Journal (Sudbury, Mass), 2003, 9, 189-204.	2.0	58
139	Chemical Genetic Blockade of Transformation Reveals Dependence on Aberrant Oncogenic Signaling. Current Biology, 2002, 12, 1386-1394.	3.9	28
140	A head holder for magnetic resonance imaging that allows the stereotaxic alignment of spontaneously occurring intracranial mouse tumors. Journal of Neuroscience Methods, 2002, 116, 1-7.	2.5	11
141	Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene, 2002, 21, 7453-7463.	5.9	66
142	Genetics of brain tumors. Current Opinion in Pediatrics, 2000, 12, 543-548.	2.0	20
143	Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO Journal, 1997, 16, 2985-2995.	7.8	709